Phytate inhibits bovine pericardium calcification in vitro

Cardiovascular Pathology

Volumn 17, Issue 3, 2008, Pages 139-145

  Grases, Félix ^a,b   Sanchis, Pilar ^a,b   Costa Bauzá, Antonia ^a,b   Bonnin, Oriol ^c   Isern, Bernat ^a,b   Perelló, Joan ^a,b   Prieto, Rafael M ^a,b  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Bovine pericardium; Cardiovascular calcification; Crystallization inhibitor; Etidronate; Phytate; Pyrophosphate

Indexed keywords

CALCIUM; ETIDRONIC ACID; GLUTARALDEHYDE; PHOSPHORUS; PHYTATE; PYROPHOSPHATE;

ANIMAL TISSUE; ARTICLE; CALCIFICATION; CONTROLLED STUDY; IN VITRO STUDY; NONHUMAN; PERICARDIUM; PERICARDIUM CALCIFICATION; PRIORITY JOURNAL;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALCINOSIS; CALCIUM; CATTLE; DIPHOSPHATES; ETIDRONIC ACID; PERICARDIUM; PHOSPHORUS; PHYTIC ACID;

EID: 43049099386     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carpath.2007.08.005     Document Type: Article

References (54)

1. Loecker T., Schwartz R., Cotta C., and Hickman J. Fluoroscopic coronary artery calcification and associated coronary disease in asymptomatic young men. J Am Coll Cardiol 19 (1992) 1167-1172
2. Puentes G., Detrano R., Twang W., Wong N., French W., Narahara K., et al. Estimation of coronary calcium mass using electron-beam computed-tomography-a promising approach for predicting coronary events. Circulation 92 (1995) 1487
3. Epple M., and Lanzer P. How much interdisciplinarity is required to understand vascular calcifications? Formulation of four basic principles of vascular calcification. Z Kardiol 90 Suppl 3 (2001) 2-5
4. Speer M., and Giachelli C. Regulation of cardiovascular calcification. Cardiovasc Pathol 13 (2004) 63-70
5. Yoshitake H., Rittling S., Denhardt D., and Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A 96 (1999) 8156-8160
6. Reinholt F., Hultenby K., Oldberg A., and Heinegard D. Osteopontin-a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A 87 (1990) 4473-4475
7. Giachelli C., Bae N., Almeida M., Denhardt D., Alpers C., and Schwartz S. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92 (1993) 1686-1696
8. O'Brien K., Kuusisto J., Reichenbach D., Ferguson M., Giachelli C., Alpers C., et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 92 (1995) 2163-2168
9. Giachelli C., Scatena M., and Wada T. Osteopontin, potential roles in vascular function and dystrophic calcification. J Bone Miner Metab 15 (1997) 179-183
10. Yasuda H., Shima N., Nakagawa N., Mochizuki S., Yano K., Fujise N., et al. Identify of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
11. Simonet W., Lacey D., Dunstan C., Kelley M., Chang M., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
12. Bucay N., Sarosi I., Dunstan C., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
13. Luo G., Ducy P., McKee M., Pinero G., Loyer E., Behringer R., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997) 78-81
14. Zebboudj A., Imura M., and Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 277 (2002) 4388-4394
15. Price P., Faus S., and Williamson M. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 18 (1998) 1400-1407
16. Levy R., Schoen F., Levy J., Nelson A., Howard S., and Oshry L. Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde-preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol 113 (1983) 143-155
17. Shen M., Marie P., Farge D., Carpentier S., De Pollak C., Hott M., et al. Osteopontin is associated with bioprosthetic heart valve calcification in humans. C R Acad Sci III 320 (1997) 49-57
18. Boskey A., Maresca M., Ullrich W., Doty S., Butler W., and Prince C. Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner 22 (1993) 147-159
19. Hunter G., and Goldberg H. Nucleation of hydroxyapatite by bone sialoprotein. Proc Natl Acad Sci U S A 90 (1993) 8562-8565
20. Hunter G., Hauschka P., Rosenberg L., Poole A., and Goldberg H. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 317 (1996) 59-64
21. Govindaraj A., and Selvam R. An oxalate-binding protein with crystal growth promoter activity from human kidney stone matrix. BJU Int 90 (2002) 336-344
22. Yamate T., Kohri K., Umekawa T., Amasaki N., Amasaki N., Isikawa Y., et al. The effect of osteopontin on the adhesion of calcium oxalate crystals to Madin-Darby canine kidney cells. Eur Urol 30 (1996) 388-393
23. Lieske J., Toback F., and Deganello S. Sialic acid-containing glycoproteins on renal cells determine nucleation of calcium oxalate dihydrate crystals. Kidney Int 60 (2001) 1784-1791
24. Lomashvili K., Cobbs S., Hennigar R., Hardcastle K., and O'Neill W. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol 15 (2004) 1392-1401
25. Price P., Buckley J., and Williamson M. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131 (2001) 2910-2915
26. Price P., Faus S., and Williamson M. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21 (2001) 817-824
27. Bevilacqua M., Dominguez L., Rosini S., and Barbagallo M. Bisphosphonates and atherosclerosis: why?. Lupus 14 (2005) 773-779
28. Grases F., Sanchis P., Perello J., Isern B., Prieto R., Fernandez-Palomeque C., et al. Phytate (myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. Front Biosci 11 (2006) 136-142
29. Webb C., Schoen F., and Levy R. Covalent binding of aminopropanehydroxydiphosphonate to glutaraldehyde residues in pericardial bioprosthetic tissue: stability and calcification inhibition studies. Exp Mol Pathol 50 (1989) 291-302
30. Levy R., Hawley M., Schoen F., Lund S., and Liu P. Inhibition by diphosphonate compounds of calcification of porcine bioprosthetic heart valve cusps implanted subcutaneously in rats. Circulation 71 (1985) 349-356
31. 6 levels in tissues and biological fluids depending on dietary phytate. J Nutr Biochem 12 (2001) 595-601
32. 6 or phytate) in humans. Biofactors 15 (2001) 53-61
33. Grases F., Simonet B., Perello J., Costa-Bauza A., and Prieto R. Effect of phytate on element bioavailability in the second generation of rats. J Trace Elem Med Biol 17 (2004) 229-234
34. Neethling W., Hodge A., and Glancy R. Glutaraldehyde-fixed kangaroo aortic wall tissue: histology, crosslink stability and calcification potential. J Biomed Mater Res B Appl Biomater 66 (2003) 356-363
35. Grases F., Costa-Bauza A., and March J. Artificial simulation of the early stages of renal stone formation. Br J Urol 74 (1994) 298-301
36. Grases F., Ramis M., and Costa-Bauza A. Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates. Urol Res 28 (2000) 136-140
37. 6) through the skin: study of the matrix effects. Mechanism of phytate topical absorption. Front Biosci 10 (2005) 799-802
38. Grases F., Perello J., Isern B., and Prieto R. Study of a myo-inositol hexaphosphate-based cream to prevent dystrophic calcinosis cutis. Br J Dermatol 152 (2005) 1022-1025
39. Grases F., Prieto R., Simonet B., and March J. Phytate prevents tissue calcifications in female rats. Biofactors 11 (2000) 171-177
40. Grases F., Perelló J., Prieto R., Simonet B., and Torres J. Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats. Life Sci 75 (2004) 11-19
41. Curhan G., Willett W., Knight E., and Stampfer M. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med 164 (2004) 885-891
42. Grases F., Isern B., Sanchis P., Perello J., Torres J., and Costa-Bauza A. Phytate acts as an inhibitor in formation of renal calculi. Front Biosci 12 (2007) 2580-2587
43. Grases F., Sanchis P., Perelló J., Isern B., Prieto R., Fernández-Palomeque C., and Torres J. Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats. Circ J 71 (2007) 1152-1156
44. Ichikawa H., Ohishi S., Takahashi O., Kobayashi H., Yuzawa K., Hosokawa N., and Hashimoto T. Acute oral toxicities of phytic acid and sodium phytate in rats. Kenkyu Nenpo-Tokyo-toritsu Eisei Kenkyusho 38 (1987) 371-376
45. Fleisch H., and Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203 (1962) 671-675
46. Fleisch H., and Neuman W. Mechanism of calcification: role of collagen, polyphosphates, and phosphatases. Am J Physiol 200 (1961) 1296-1300
47. Fleisch H., Russell R., Bisaz S., Muhlbauer R., and Williams D. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest 1 (1970) 12-18
48. Middlemost S., Sussman M., Patel A., and Manga P. The stentless quadrileaflet bovine pericardial mitral valve: early clinical results. J Heart Valve Dis 8 (1999) 174-179
49. Arcidiacono G., Corvi A., and Severi T. Functional analysis of bioprosthetic heart valves. J Biomech 38 (2005) 1483-1490
50. Mavrilas D., Kapolos J., Koutsoukos P., and Dougenis D. Screening biomaterials with a new in vitro method for potential calcification: porcine aortic valves and bovine pericardium. J Mater Sci Mater Med 15 (2004) 699-704
51. Dorozhkin S., and Dorozhkina E. A first approach to in vitro simulation of vascular calcification by the controlled crystallization of poorly crystalline calcium phosphates onto porous cholesterol. Proc Inst Mech Eng [H] 219 (2005) 477-482
52. Peters F., and Epple M. Simulating arterial wall calcification in vitro: biomimetic crystallization of calcium phosphates under controlled conditions. Z Kardiol 90 Suppl 3 (2001) 81-85
53. Park J., Hwang Y., Han D., and Suh H. A novel in vitro assessment of tissue valve calcification by a continuous flow type method. Artif Organs 24 (2000) 158-160
54. Pettenazzo E., Deiwick M., Thiene G., Molin G., Glasmacher B., Martignago F., et al. Dynamic in vitro calcification of bioprosthetic porcine valves: evidence of apatite crystallization. J Thorac Cardiovasc Surg 121 (2001) 500-509